Peptic ulcer within the past 3 months prior to randomization, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD)
History of peptic ulcer disease within 3 months of treatment.
History within 3 months prior to treatment of grade 3-4 gastrointestinal (GI) bleeding/hemorrhage, treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolus, or other uncontrolled thromboembolic event
History of gastrointestinal bleeding, gastric stress ulcerations, or peptic ulcer disease within the past 3 months prior to randomization that, in the investigator's opinion, may place the patient at risk of side effects from anti-angiogenesis products.
Ongoing or active gastritis or peptic ulcer disease.
Participant has active peptic ulcer disease or other hemorrhagic esophagitis/gastritis, enteritis, colitis.
Uncontrolled or active gastric or duodenal ulcer disease within 30 days of enrollment
History of gastrointestinal fistula, hemorrhage, perforation or peptic ulcer disease
History of peptic ulcer within the past 3 months prior to study treatment, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 28 days prior to study treatment
Active peptic ulcer disease even if asymptomatic
Patients with a history of peptic ulcer disease or gastrointestinal bleeding
Active peptic ulcer disease for lesions within 5 cm of the stomach
History of peptic ulcer disease requiring treatment within the last 5-years
Active peptic ulcer disease
History of peptic ulcer disease or erosive gastritis within the past 3 months, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 28 days of starting study treatment
Patients must not have nor had active or recent peptic ulcer disease within the past 6 months\r\n* Patients with active significant symptoms of dyspepsia will be excluded
DONOR: Active peptic ulcer disease
Subjects with an acute gastrointestinal ulcer
Ongoing or active gastritis or peptic ulcer disease.
Active peptic ulcer disease defined as unhealed or clinically active
Active gastritis or active peptic ulcer
No uncontrolled gastric ulcer disease (grade 3 gastric ulcer disease) within 28 days of registration
History within 3 months prior to treatment of grade 3-4 gastrointestinal (GI) bleeding/hemorrhage, treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolus, or other uncontrolled thromboembolic event
Subjects with history of anaphylaxis or angioedema, bronchial asthma, peptic ulcer\n             and clinically significant food or drug allergy
Patient must have no active peptic ulcer disease
History of peptic ulcer within the past 3 months of treatment, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 28 days of starting study treatment
History of peptic ulcer disease within 3 months of treatment, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 28 days of starting study treatment
Clinically significant gastritis or peptic ulcer disease that would contraindicate the use of indomethacin.
Active peptic ulcer disease even if asymptomatic
Patients with history of gastrointestinal (GI) bleeding and peptic ulcer disease within the past 6 months
Malabsorption or uncontrolled peptic ulcer disease
Active uncontrolled gastric or duodenal ulcer
No known contraindications to anti-angiogenics such as severe coronary artery disease, recent myocardial infarction or stroke within 6 months, bleeding peptic ulcer or varices within last 3 months, and any other major illness that may jeopardize study treatment or follow up
History of treatment-resistant peptic ulcer disease, erosive esophagitis, gastritis, or diverticulitis within 3 months
No discrete gastric or duodenal ulcer greater than 5 mm within the past year except Helicobacter pylori-related peptic ulcer disease treated with antibiotics.
History of peptic ulcer within the last 6 months
E 11. Any of the following within 3 months prior to randomization: treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolism, or other uncontrolled thromboembolic event.
Active peptic ulcer disease
Active peptic ulcer disease or other potentially hemorrhagic esophagitis/gastritis
Uncontrolled inflammatory bowel disease, peptic ulcer disease or history of significant gastro intestinal bleeding within 6 months of enrollment.
History of perforation or bleeding related to peptic ulcer disease
Active peptic ulcer
History of intra-abdominal inflammatory process within 6 months prior to Day 1 of Cycle 1 including but not limited to peptic ulcer disease, diverticulitis, or colitis
Uncontrolled peptic or gastric ulcer disease, or gastrointestinal bleeding within prior 6 months
Any of the following within 3 months prior to study entry: grade 3-4 gastrointestinal bleeding/hemorrhage, treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolism or other uncontrolled thromboembolic event
Subject has active peptic ulcer disease or other hemorrhagic esophagitis/gastritis
No active peptic ulcer disease
History of peptic ulcer disease or hemorrhagic gastritis within 6 months of TRC105 administration, unless patient has received adequate treatment for peptic ulcer disease or hemorrhagic gastritis and has evidence of complete resolution documented by esophagogastroduodenoscopy (EGD); mild gastritis is allowed
Patients with a history of peptic ulcer disease
Patients with bradycardia, seizure disorder or peptic ulcer disease (PUD)
Will exclude patients with current, active peptic ulcer disease
Gastrointestinal obstruction or an active peptic ulcer
3. Participant has active peptic ulcer disease or other hemorrhagic esophagitis/gastritis.
Patient condition associated with a high risk of bleeding such as recent surgery or peptic ulcer disease
Active peptic ulcer disease or evidence of gastrointestinal bleed
Patients with active peptic ulceration
Active peptic ulcer disease
History of\r\n* Any invasive malignancy within the past 2 years, with the exception of non-melanoma skin cancer\r\n* Chronic renal diseases or liver cirrhosis\r\n* Diseases such as anemia, peptic ulcer, gastrointestinal bleeding, active colitis and inflammatory bowel disease\r\n* Hemorrhagic stroke or uncontrolled hypertension
Individuals with active gastroduodenal ulcer disease in the preceding 5 years
History of endoscopically or radiographically diagnosed peptic ulcer disease with upper GI bleeding during the past 5 years or history of endoscopically or radiographically diagnosed peptic ulcer disease with upper GI bleeding any time while taking aspirin
Has history of herpetic infection, recurrent aphthous ulcer, or other ulcer forming diseases, abscesses, granulomas, or severe gingivitis
Prior history of gastrointestinal (GI) perforation, diverticulitis, and/or peptic ulcer disease
No active peptic ulcer disease
Have a history of peptic ulcer disease within the last 12 months unless adequately treated as assessed by the participant’s primary care physician or medical oncologist
History of peptic ulcer disease or erosive gastritis within the past 6 months, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 28 days of starting study treatment